Molecular diagnostic methods for predicting brain metastasis of breast cancer
Disclosed are molecular diagnostic compositions and methods for predicting brain metastasis of breast cancer, as well as methods for drug repositioning to identify existing and new therapeutics for use in developing individualized, patient-specific treatment regimens for improving diagnoses and patient outcomes in individuals at risk for brain metastasis of breast cancer.
1. A method of treating brain metastasis of breast cancer in a human patient, the method comprising:
assaying the mRNA levels of seven biomarkers in a primary breast cancer sample obtained from a patient having brain metastasis of breast cancer, wherein the seven biomarkers are selected from the group consisting of ret proto-oncogene (RET), proto-oncogene tyrosine-protein kinase Fyn (FYN), kinase insert domain receptor (KDR), RAF proto-oncogene serine/threonine-protein kinase (RAF1), NF-kappa-B p105 subunit (NFKB1), histone deacetylase 1 (HDAC1), and histone deacetylase 2 (HDAC2);
determining that the mRNA level of RET, FYN, or KDR is higher than a corresponding control level in primary breast cancer samples obtained from control subjects without brain metastasis of breast cancer; and
administering to the patient (i) Sunitinib when the mRNA level of RET or KDR is higher or, in the alternative, (ii) Dasatinib when the mRNA level of FYN is higher.
2. The method of claim 1 , wherein the expression level of KDR is higher in the primary breast cancer sample and the drug administered is Sunitinib.
3. The method of claim 1 , wherein the expression level of FYN is higher in the primary breast cancer sample and the drug administered is Dasatinib.
4. The method of claim 1 , wherein the expression level of RET is higher in the primary breast cancer sample and the drug administered is Sunitinib.
5. The method of claim 1 , wherein the assaying step is carried out with RT-PCR.